Author

Esa Kari

Observed names: E. Kari, ESA JARKKO MIKAEL KARI, Esa J. M. Kari, Esa Jarkko Mikael Kari

Institutions: Tampere University, Tampere University Hospital

Observed institutions: Tampere University, Oulu University Hospital, Tampere University Hospital, University of Oulu

ORCID: 0000-0002-7165-8120

Observed ORCID: 0000-0002-7165-8120

OpenAlex ID: A5085609259

Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020

2022 · Minna Harmanen, Mika Hujo, et al. · British Journal of Haematology · 25

Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP

2019 · Esa Kari, Hanna-Riikka Teppo, et al. · Journal of Clinical Pathology · 16

Testis‐Specific Thioredoxins TXNDC2, TXNDC3, and TXNDC6 Are Expressed in Both Testicular and Systemic DLBCL and Correlate with Clinical Disease Presentation

2021 · Mikko C. Chan, Janette Savela, et al. · Oxidative Medicine and Cellular Longevity · 4

Thioredoxin‐1 as a biological predictive marker for selecting diffuse large B‐cell lymphoma patients for etoposide‐containing treatment

2020 · Esa Jarkko Mikael Kari, Milla Elvi Linnea Kuusisto, et al. · European Journal Of Haematology · 4

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data

2025 · Minna Harmanen, Mika Hujo, et al. · Hematological Oncology · 1

Front‐line and second‐line treatment for mantle cell lymphoma in clinical practice: A multicenter retrospective analysis

2024 · Minna Harmanen, Marc Sorigue, et al. · European Journal Of Haematology · 1

Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria

2023 · Minna Harmanen, Tuula Klaavuniemi, et al. · HemaSphere · 1

Lifetime Treatment Burden of Patients With Mantle Cell Lymphoma: Simulation‐based Analysis of Real‐world Data From 20 Years

2023 · M. E. Harmanen, M. Hujo, et al. · Hematological Oncology

Clinical impact of antioxidant enzymes Prx6 and Trx and their regulators Nrf1 and Nrf2 in diffuse Large B-cell lymphoma

2020 · Esa Kari

Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma

2019 · ESA JARKKO MIKAEL KARI, MILLA ELVI LINNEA KUUSISTO, et al. · Anticancer Research

Works count: 10

Citation count: 52

H-index: 4

I10-index: 2